Latest News

Opinion: Working with ICER, or around it, on cost-effectiveness estimates

As the national debate over prescription drug pricing reaches a fever pitch, drug manufacturers bringing new products to market face unique challenges. From the threats of political oversight and media scrutiny to academic guesstimates on the value of these products, the current environment for bringing breakthrough treatments to market is marked by unprecedented scrutiny. Perhaps nowhere is this more apparent than in the burgeoning world of cost-effectiveness analysis.

In this exercise, health care researchers rely on a variety of data to try to quantify how much a treatment extends life and improves health. The result of cost-effectiveness analyses is often a threshold — or a range of prices — at which researchers believe the treatment would be worth paying for.

Read the rest…

Source link

Related posts

Veterans Health Administration dialysis providers linked with lower mortality rates, increased hospitalization rates


Trump’s $500 million for childhood cancer? Scientists have ideas how to spend it


Teenagers have a hard time reading one another's tones of voice


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy